SCYX: SCYNEXIS Inc Operating Profitability

SCYNEXIS, Inc. - graphic logo of issuer SCYX

The EBIT margin of SCYNEXIS, Inc. (SCYX) demonstrates the impact of Brexafemme's patent protection and partner support on business stability. The unique mechanism of action of new antibiotics provides a competitive advantage in treating resistant fungi. Revenues are based on the sale of candidiasis therapy and royalties from GSK, while -126.90 forms the current metric, determining the efficiency of core operations before taxes.

SCYNEXIS Inc (SCYX): Profitability of Operations from 07/04/2022 to 11/19/2026

Metric breakdowns and analytics for Scynexis (SCYX)

- price and consensus price forecast:
- market capitalization information:
General company analysis:SCYNEXIS, Inc., SCYX
Brand item of SCYNEXIS Inc

Investors are assessing the resilience of SCYNEXIS, Inc. (SCYX) through the efficiency of cost management during the transition to a licensing model to mitigate the risks of single-product dependency. When analyzing the history of operating profitability, one should consider the operating margin, which demonstrates the business's actual return on each unit of revenue before accounting for financial obligations and taxes.